About TorreyPines Therapeutics, Inc.
TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity, xerostomia and cognitive disorders. The company is currently developing three product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at http://www.torreypinestherapeutics.com.
This press release contains forward-looking statements or predictions.
Such statements are subject to numerous known and unknown risks,
uncertainties and other factors, which may cause TorreyPines' actual
results to be materially different from historical results or from any
results expressed or implied by such forward-looking statements. These and
other risks which may cause results to differ are described in greater
detail in the "Risk Factors" section of TorreyPines' annual report on Form
10-K for the year ended December 31, 2007 and TorreyPines other SEC
reports. The forward-looking statements are based on current information
that is likely to change and speak only as of the date hereof.
Company contact: Investor contact:
Paul Schneider Rhonda Chiger
TorreyPines Therapeutics, Inc. Rx Communications Group
|SOURCE TorreyPines Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved